JOP20190115A1 - مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) - Google Patents

مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)

Info

Publication number
JOP20190115A1
JOP20190115A1 JOP/2019/0115A JOP20190115A JOP20190115A1 JO P20190115 A1 JOP20190115 A1 JO P20190115A1 JO P20190115 A JOP20190115 A JO P20190115A JO P20190115 A1 JOP20190115 A1 JO P20190115A1
Authority
JO
Jordan
Prior art keywords
parp
adp
ribose
polymerase
poly
Prior art date
Application number
JOP/2019/0115A
Other languages
English (en)
Inventor
Taisuke Takahashi
Arthur Kluge
Bharat Lagu
Nan Ji
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of JOP20190115A1 publication Critical patent/JOP20190115A1/ar
Application granted granted Critical
Publication of JOP20190115B1 publication Critical patent/JOP20190115B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلانية مشتملة على مادة حاملة أو مادة مخفِّفة مقبولة صيدلانياً ومركب ممثل بواسطة الصيغة البنائية التالية: ويتعلق الاختراع الحالي بطريقة لعلاج خاضع للعلاج يعاني من مرض يمكن تخفيفه بتثبيط إنزيم بولي (<span dir="LTR">ADP</span>-ريبوز) بوليمراز (<span dir="LTR">PARP</span>). يوفر الطلب الحالي تعريفات للمتغيرات. شكل 1.
JOP/2019/0115A 2016-12-30 2017-12-28 مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) JOP20190115B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662440581P 2016-12-30 2016-12-30
PCT/US2017/068636 WO2018125961A1 (en) 2016-12-30 2017-12-28 Poly-adp ribose polymerase (parp) inhibitors

Publications (2)

Publication Number Publication Date
JOP20190115A1 true JOP20190115A1 (ar) 2019-05-20
JOP20190115B1 JOP20190115B1 (ar) 2023-09-17

Family

ID=61007849

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0115A JOP20190115B1 (ar) 2016-12-30 2017-12-28 مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)

Country Status (33)

Country Link
US (2) US11034670B2 (ar)
EP (1) EP3562822B1 (ar)
JP (1) JP7141399B2 (ar)
KR (1) KR102606799B1 (ar)
CN (1) CN110167926B (ar)
AR (1) AR110706A1 (ar)
AU (1) AU2017388376B2 (ar)
CA (1) CA3047137A1 (ar)
CO (1) CO2019007906A2 (ar)
CY (1) CY1124565T1 (ar)
DK (1) DK3562822T3 (ar)
EA (1) EA201991412A1 (ar)
ES (1) ES2875841T3 (ar)
HR (1) HRP20210887T1 (ar)
HU (1) HUE054382T2 (ar)
IL (1) IL267676B (ar)
JO (1) JOP20190115B1 (ar)
LT (1) LT3562822T (ar)
MA (1) MA47165B1 (ar)
MD (1) MD3562822T2 (ar)
MX (1) MX393606B (ar)
MY (1) MY199045A (ar)
PH (1) PH12019501529A1 (ar)
PL (1) PL3562822T3 (ar)
PT (1) PT3562822T (ar)
RS (1) RS61895B1 (ar)
SA (1) SA519401894B1 (ar)
SI (1) SI3562822T1 (ar)
SM (1) SMT202100321T1 (ar)
TW (1) TWI773718B (ar)
UA (1) UA124777C2 (ar)
WO (1) WO2018125961A1 (ar)
ZA (2) ZA201904004B (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102667386B1 (ko) * 2015-10-07 2024-05-21 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
MX393606B (es) * 2016-12-30 2025-03-19 Mitobridge Inc Inhibidores de poli-adp ribosa polimerasa (parp)
US12459899B2 (en) 2019-10-30 2025-11-04 DIGMBIO, Inc. Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient
CA3213029A1 (en) * 2021-04-22 2022-10-27 Yuli Xie Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
CN118076585A (zh) * 2021-07-23 2024-05-24 国家医疗保健研究所 革兰氏阴性菌外排泵抑制剂
CN113603630B (zh) * 2021-08-10 2023-06-27 苏州小栗医药科技有限公司 一种4-苯基哌啶盐酸盐的合成方法
JP2025531246A (ja) 2022-09-19 2025-09-19 ビーエーエスエフ ソシエタス・ヨーロピア アゾール系殺有害生物化合物
AU2023377192A1 (en) 2022-11-07 2025-05-22 Kyoto University Nitrogen-containing heterocyclic compound
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN120917007A (zh) * 2023-05-19 2025-11-07 上海海和药物研究开发股份有限公司 一种芳基脲类parp1抑制剂、其制备方法及用途
CN117024357B (zh) * 2023-07-03 2026-02-24 山东第二医科大学 一种针对brca突变的选择性抑制剂及其用途
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
CN117510404A (zh) * 2023-11-29 2024-02-06 山西永津集团有限公司 一种4-氨基烟酸的制备方法
WO2025111705A1 (en) * 2023-11-30 2025-06-05 Waverley Pharma Inc. Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
CN118084678B (zh) * 2024-03-01 2024-09-06 长沙唯楚医药科技有限公司 一种2-溴-6-氟苯胺的制备方法
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025227032A1 (en) * 2024-04-26 2025-10-30 Remix Therapeutics Inc. Methods for degradation of cyclin k and inhibition of cyclin dependent kinases
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082268A1 (en) 2000-03-20 2002-06-27 Yun Gao Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
US20030087917A1 (en) 2000-03-27 2003-05-08 Dorothea Strack Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2005082887A1 (ja) 2004-02-26 2005-09-09 Aska Pharmaceutical Co., Ltd. ピリミジン誘導体
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
MXPA06014933A (es) * 2004-06-30 2007-02-28 Janssen Pharmaceutica Nv Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1.
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
WO2007011623A1 (en) 2005-07-15 2007-01-25 Schering Corporation Quinazoline derivatives useful in cancer treatment
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
WO2012140642A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
AU2014298955B2 (en) 2013-07-31 2018-03-01 Merck Patent Gmbh Oxoquinazolinyl-butanamide derivatives
CA2948067A1 (en) 2014-05-07 2015-11-12 Merck Patent Gmbh Heterocyclyl-butanamide derivatives
CN105924434A (zh) * 2015-02-28 2016-09-07 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
US11186564B2 (en) 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
MX393606B (es) * 2016-12-30 2025-03-19 Mitobridge Inc Inhibidores de poli-adp ribosa polimerasa (parp)

Also Published As

Publication number Publication date
PH12019501529A1 (en) 2020-09-14
EP3562822B1 (en) 2021-03-10
CN110167926A (zh) 2019-08-23
WO2018125961A8 (en) 2019-05-23
US11993585B2 (en) 2024-05-28
IL267676A (en) 2019-08-29
EA201991412A1 (ru) 2019-11-29
WO2018125961A1 (en) 2018-07-05
HUE054382T2 (hu) 2021-09-28
MA47165B1 (fr) 2021-06-30
US20200071299A1 (en) 2020-03-05
CN110167926B (zh) 2022-09-13
AU2017388376A1 (en) 2019-07-04
MX2019007870A (es) 2019-08-16
LT3562822T (lt) 2021-06-10
SI3562822T1 (sl) 2021-08-31
HRP20210887T1 (hr) 2021-07-23
JP7141399B2 (ja) 2022-09-22
EP3562822A1 (en) 2019-11-06
ZA201904004B (en) 2022-12-21
MD3562822T2 (ro) 2021-07-31
PT3562822T (pt) 2021-06-02
CY1124565T1 (el) 2022-07-22
DK3562822T3 (en) 2021-05-03
SA519401894B1 (ar) 2023-02-19
US11034670B2 (en) 2021-06-15
JP2020512298A (ja) 2020-04-23
MX393606B (es) 2025-03-19
BR112019011676A2 (pt) 2019-10-15
TWI773718B (zh) 2022-08-11
JOP20190115B1 (ar) 2023-09-17
TW201834657A (zh) 2018-10-01
SMT202100321T1 (it) 2021-07-12
PL3562822T3 (pl) 2021-09-13
ES2875841T3 (es) 2021-11-11
MA47165A (fr) 2019-11-06
AU2017388376B2 (en) 2022-01-06
KR20190098760A (ko) 2019-08-22
ZA202003310B (en) 2021-08-25
KR102606799B1 (ko) 2023-11-28
US20220033380A1 (en) 2022-02-03
AR110706A1 (es) 2019-04-24
RS61895B1 (sr) 2021-06-30
NZ754385A (en) 2024-07-05
UA124777C2 (uk) 2021-11-17
MY199045A (en) 2023-10-11
CO2019007906A2 (es) 2019-10-21
IL267676B (en) 2021-09-30
CA3047137A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
JOP20190115A1 (ar) مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)
NI201800093A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer
PH12017501016A1 (en) Triazolopyrimidine compounds and uses thereof
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX374439B (es) Compuesto de piridona como inhibidor de c-met
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
ZA201701299B (en) Glycosidase inhibitors
EA201690094A1 (ru) Ингибиторы syk
MX2018010192A (es) Inhibidores de glucosidasa.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
AR099376A1 (es) Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
NZ746906A (en) Oxaborole esters and uses thereof
EA201690763A1 (ru) Лечение рака поджелудочной железы
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor